Daiwa Securities Group Inc. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$10
-23.1%
2820.0%0.00%
Q2 2023$13
+18.2%
2820.0%0.00%
Q1 2023$11
-15.4%
2820.0%0.00%
Q4 2022$13
-99.9%
282
+8.0%
0.00%
Q3 2022$11,000
-31.2%
2610.0%0.00%
Q2 2022$16,000
+14.3%
261
+31.2%
0.00%
Q1 2022$14,000
-17.6%
1990.0%0.00%
Q4 2021$17,000
-19.0%
199
-14.2%
0.00%
Q3 2021$21,000
+61.5%
232
+74.4%
0.00%
Q2 2021$13,000
-13.3%
1330.0%0.00%
Q1 2021$15,000
-11.8%
133
+7.3%
0.00%
Q4 2020$17,000
-39.3%
124
-63.5%
0.00%
Q3 2020$28,000
+100.0%
340
+4.3%
0.00%
Q2 2020$14,0000.0%3260.0%0.00%
Q1 2020$14,0000.0%3260.0%0.00%
Q4 2019$14,000
-6.7%
326
-8.9%
0.00%
Q3 2019$15,000
-34.8%
3580.0%0.00%
Q2 2019$23,000
-8.0%
3580.0%0.00%
Q1 2019$25,000
+127.3%
358
+37.7%
0.00%
Q4 2018$11,000
-45.0%
2600.0%0.00%
Q3 2018$20,0000.0%2600.0%0.00%
Q2 2018$20,000
+53.8%
2600.0%0.00%
Q1 2018$13,0002600.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2021
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders